| 14.76 -0.02 (-0.14%) | 02-06 10:39 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 19.43 | 1-year : | 22.7 |
| Resists | First : | 16.63 | Second : | 19.43 |
| Pivot price | 14.72  |
|||
| Supports | First : | 14.01 | Second : | 12.39 |
| MAs | MA(5) : | 14.34 |
MA(20) : | 14.35 |
| MA(100) : | 16.03  |
MA(250) : | 20.19 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 49.7 |
D(3) : | 43.4 |
| RSI | RSI(14): 51.9 |
|||
| 52-week | High : | 31.03 | Low : | 11.69 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ PRTA ] has closed below upper band by 47.5%. Bollinger Bands are 15.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.12 - 15.19 | 15.19 - 15.25 |
| Low: | 13.98 - 14.06 | 14.06 - 14.13 |
| Close: | 14.64 - 14.78 | 14.78 - 14.9 |
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Tue, 04 Feb 2025
Q2 Earnings Forecast for Prothena Issued By Zacks Research - MarketBeat
Sun, 26 Jan 2025
Duncan Williams Asset Management LLC Has $958,000 Position in Prothena Co. plc (NASDAQ:PRTA) - MarketBeat
Fri, 24 Jan 2025
Insufficient Growth At Prothena Corporation plc (NASDAQ:PRTA) Hampers Share Price - Simply Wall St
Fri, 17 Jan 2025
Trading (PRTA) With Integrated Risk Controls - Stock Traders Daily
Mon, 30 Dec 2024
Prothena Director Oleg Nodelman Steps Down After 5-Year Tenure, Ahead of Major 2025 Clinical Milestones - StockTitan
Mon, 30 Dec 2024
Prothena Announces Board of Directors Update - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 54 (M) |
| Held by Insiders | 3.837e+007 (%) |
| Held by Institutions | 13.4 (%) |
| Shares Short | 8,800 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.6723e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -98.9 % |
| Operating Margin | -6 % |
| Return on Assets (ttm) | 857 % |
| Return on Equity (ttm) | -15.7 % |
| Qtrly Rev. Growth | 1.3335e+008 % |
| Gross Profit (p.s.) | -618.13 |
| Sales Per Share | -143.13 |
| EBITDA (p.s.) | -6.30562e+008 |
| Qtrly Earnings Growth | -2.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -153 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.11 |
| Price to Cash Flow | 0.23 |
| Dividend | 0 |
| Forward Dividend | 9.35e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|